The blood pressure medication felodipine could potentially be “repurposed” as a treatment for neurodegenerative diseases such as Parkinson, Alzheimer, and Huntington diseases, according to findings from a recent study.
The blood pressure medication felodipine could potentially be “repurposed” as a treatment for neurodegenerative diseases such as Parkinson, Alzheimer, and Huntington diseases, according to findings from a recent study.
Commonly found in most neurodegenerative diseases is the accumulation of aggregate-prone proteins within the cytoplasm of neurons. Such proteins cause pathology “via toxic gain-of-function mechanisms,” wrote the authors. “Thus, the factors regulating their clearance are likely to be important for understanding pathogenesis and developing rational therapeutic strategies.”
The researchers found that felodipine administration in mice at concentrations mimicking those seen in humans can induce autophagy and reduce levels of neurotoxic proteins. This was done by inserting “minipumps” underneath the mice’s skin to enable drug concentration levels similar to those in humans and to keep the levels steady without any major fluctuations.
“This is the first time that we’re aware of that a study has shown that an approved drug can slow the buildup of harmful proteins in the brains of mice using doses aiming to mimic the concentrations of the drug seen in humans,” said David Rubinsztein, BSc, PhD, FRCPath, FMedSci, FRS, a professor of molecular neurogenetics at the University of Cambridge, in an interview.
The study notes that as of now, there are no current treatments for neurodegenerative diseases that use autophagy inducers. While it is possible to start from scratch to develop new experimental drugs for this specific target, it would be more cost-effective and timely to search for candidates among the drugs that are already approved and test them for a new condition.
Overall, the authors were able to conclude that “Our data with this minipump administration suggest that at human-like plasma concentrations, felodipine can induce autophagy in the brains of mice and clear aggregate-prone disease-causing proteins.”
Reference
Siddiqi F, Menzies F, Lopez A, et al. Felodipine induces autophagy in mouse brains with pharmacokinetics amenable to repurposing [published online April 18, 2019]. Nature Comm. doi: 10.1038/s41467-019-09494-2.
Major Study Expands in Hopes to Cure Parkinson Disease
April 19th 2022April is Parkinson’s Disease Awareness month, and on this episode of Managed Care Cast, we take a look at the Parkinson's Progression Markers Initiative (PPMI), a study from the Michael J. Fox Foundation for Parkinson's Research (MJFF). The multicenter, international study aims to end Parkinson disease, which is expected to double worldwide by 2040, to more than 14 million people.
Listen
Certain Patient Groups Continue to Be Underrepresented in PD Studies in the Netherlands
February 4th 2023With greater attention being paid to the heterogenous patient population, researchers questioned whether this has resulted in a more diverse group of patients included in Parkinson disease (PD) studies in the Netherlands.
Read More
An Inside Look at Innovations by MJFF to Assist the Parkinson Community Amid the COVID-19 Pandemic
May 26th 2020On this episode of Managed Care Cast, we speak with Rachel Dolhun, MD, vice president of Medical Communications at The Michael J. Fox Foundation for Parkinson Research, about recent innovations by The Michael J. Fox Foundation to assist patients and families of patients with Parkinson disease in adjusting to this new normal.
Listen
Motor Symptoms May Occur 3 Years Before Parkinson Disease Diagnosis, Study Says
January 20th 2023Trouble with balance and holding objects above one's head were just a few of the problems reported by patients 3 years before they received a formal Parkinson disease diagnosis, according to a recent study.
Read More